NurExone Biologic Inc. (formerly, EnerSpar Corp.) is a listed company. Filings by its managers are published through SEDI. Over the twelve months to 18 October 2026, 5 filings were filed, from 5 insiders.
Not one of the filings records a straightforward purchase or sale on the market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
For context, the typical company on the same exchange (median of 2,144 companies) published 12 filings over the same period, against 5 filings here.
No insider has bought NurExone Biologic Inc. (formerly, EnerSpar Corp.) shares on the open market in the past twelve months. Typically, a trade is published a median of 7 days after it takes place. The shorter that gap, the sooner other investors can see what insiders have done.
Source: insider filings from SEDI. Past trades are no guide to future returns.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
FY ended December 2025 · cache
12 of 12 declarations
NurExone Biologic Inc. is a biotechnology company focused on developing innovative treatments for neurodegenerative diseases. Formerly known as EnerSpar Corp., it is listed on the XTSE.